NDA 016812 · Ph Health
Ketalar
Ketamine Hydrochloride · Injection
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Mar 23, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1970
Feb 19, 1970
Approved uses
2
Original approval plus efficacy supplements
Registered trials
1,644
253 Phase 3, 181 recruiting
FAERS reports
5,133
3,592 serious, 562 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 2, 2026.
KETALAR (ketamine hydrochloride) injection is indicated: as the sole anesthetic agent for diagnostic and surgical procedures that do not require skeletal muscle relaxation. for the induction of anesthesia prior to the administration of other general anesthetic agents. as a supplement to other anesthetic agents. KETALAR is a general anesthetic indicated: as the sole anesthetic agent for diagnostic and surgical procedures that do not require skeletal muscle relaxation (1) for the induction of anesthesia prior to the administration of other general anesthetic agents (1) as a supplement to other anesthetic agents (1).
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 11, 1982 Supplement 23 · Efficacy
- Feb 19, 1970 Original approval · Type 1 - New Molecular Entity · priority review
3 products under this application
- KETALAR · KETAMINE HYDROCHLORIDE EQ 10MG BASE/ML · INJECTABLE, INJECTION · Prescription · TE AP
- KETALAR · KETAMINE HYDROCHLORIDE EQ 50MG BASE/ML · INJECTABLE, INJECTION · Prescription · TE AP
- KETALAR · KETAMINE HYDROCHLORIDE EQ 100MG BASE/ML · INJECTABLE, INJECTION · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Ketamine" as an intervention, any sponsor and status, largest first.
Vanderbilt UniversityAcademic, hospital or other
NCT02625181 · 27,034 participants · Start Jul 2016 · Primary completion Nov 2, 2017
Drug: Propofol; Sevoflurane and 28 more · For: Postoperative Nausea and Vomiting
Sites: Nashville, Tennessee
- Safety and Efficacy Evaluation of S (+) - Ketamine in AdultsPivotal-lookingStatus unknown
Chinese PLA General HospitalAcademic, hospital or other
NCT04837170 · 12,000 participants (planned) · Start May 1, 2021 · Primary completion Jun 1, 2022
Drug: Conventional therapy + S (+)-Ketamine; Conventional therapy · For: Postoperative Pain; Adults; Anesthesia
- Anesthesia and Non-small Cell Lung Cancer RecurrencePivotal-lookingRecruiting
Samsung Medical CenterAcademic, hospital or other
NCT06330038 · 5,384 participants (planned) · Start Aug 5, 2024 · Primary completion Dec 31, 2028
Drug: Propofol; Inhaled anesthetics · For: Non-small Cell Lung Cancer; Surgery; Anesthesia
Sites: Seoul, South Korea
- Safety and Efficacy Evaluation of S (+) - Ketamine in ChildrenPivotal-lookingStatus unknown
Chinese PLA General HospitalAcademic, hospital or other
NCT04834427 · 3,000 participants (planned) · Start Apr 20, 2022 · Primary completion Dec 1, 2024
Drug: Conventional therapy + S (+)-Ketamine; Conventional therapy · For: S-ketamine; Esketamine; Acute Pain and 6 more
Sites: Beijing, China
- Randomized Trial of Sedative Choice for IntubationPivotal-lookingCompleted
Vanderbilt University Medical CenterAcademic, hospital or other
NCT05277896 · 2,367 participants · Start Apr 6, 2022 · Primary completion Sep 6, 2025
Drug: Ketamine; Etomidate · For: Acute Respiratory Failure
Sites: Birmingham, Alabama; Aurora, Colorado; Denver, Colorado · 6 sites in all
- Dexmedetomidine-esketamine and tDCS for Prevention of Neurocognitive Complications After SurgeryPivotal-lookingNot yet recruiting
Peking University First HospitalAcademic, hospital or other
NCT07576517 · 1,996 participants (planned) · Start Oct 2026 · Primary completion Dec 2029
Drug: Dex-Esk; Placebo · For: Older Patients; Surgery; Dexmedetomidine and 3 more
Sites: Beijing, China; Fuzhou, China; Shenzhen, China · 6 sites in all
- Long-term Follow-up of Dexmedetomidine-esketamine and tDCS for Neurocognitive Complications After SurgeryPivotal-lookingNot yet recruiting
Peking University First HospitalAcademic, hospital or other
NCT07576543 · 1,996 participants (planned) · Start Oct 2026 · Primary completion Dec 2030
Drug: Dex-Esk; Placebo · For: Older Patients; Surgery; Dexmedetomidine and 4 more
Sites: Beijing, China; Fuzhou, China; Shenzhen, China · 6 sites in all
- Effect of Dexmedetomidine and Esketamine on Catheter-related Bladder DiscomfortPivotal-lookingRecruiting
Peking University First HospitalAcademic, hospital or other
NCT06399185 · 1,740 participants (planned) · Start Jun 6, 2024 · Primary completion Apr 2027
Drug: Normal saline; Dexmedetomidine and 2 more · For: Urinary Catheter; Catheter-related Bladder Discomfort; Dexmedetomidine and 1 more
Sites: Beijing, China; Shenzhen, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- infusion site pain797
- drug ineffective564
- nausea545
- off label use539
- infusion site erythema501
- infusion site swelling347
- headache342
- diarrhoea317
- drug abuse315
- dyspnoea313
- hyperhidrosis238
- fatigue237
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 20 |
| 2005 | 20 |
| 2006 | 5 |
| 2007 | 35 |
| 2008 | 28 |
| 2009 | 59 |
| 2010 | 94 |
| 2011 | 61 |
| 2012 | 83 |
| 2013 | 84 |
| 2014 | 104 |
| 2015 | 94 |
| 2016 | 114 |
| 2017 | 84 |
| 2018 | 64 |
| 2019 | 143 |
| 2020 | 114 |
| 2021 | 194 |
| 2022 | 240 |
| 2023 | 563 |
| 2024 | 1,079 |
| 2025 | 1,106 |
| 2026 | 744 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Ketamine Versus Etomidate for Rapid Sequence Intubation: A Systematic Review and Meta-Analysis of Randomized Trials.
Greer A, Hewitt M, Khazaneh PT, et al. · Crit Care Med 2025 · Systematic Review, Meta-Analysis
- Ketamine Infusions for Chronic Pain: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Orhurhu V, Orhurhu MS, Bhatia A, et al. · Anesth Analg 2019 · Meta-Analysis, Research Support, U.S. Gov't, Non-P.H.S.
- Ketamine Pharmacokinetics.
Kamp J, Olofsen E, Henthorn TK, et al. · Anesthesiology 2020 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis.
Bahji A, Vazquez GH, Zarate CA · J Affect Disord 2021 · Meta-Analysis, Systematic Review
- A systematic review and meta-analysis of ketamine in pediatric status epilepticus.
Chiriboga N, Spentzas T, Abu-Sawwa R · Epilepsia 2024 · Systematic Review, Meta-Analysis
- Real-world effectiveness of ketamine in treatment-resistant depression: A systematic review & meta-analysis.
Alnefeesi Y, Chen-Li D, Krane E, et al. · J Psychiatr Res 2022 · Meta-Analysis, Systematic Review
Sponsor: Ph Health
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.